Non–Small Cell Lung Cancer Coverage from Every Angle

Egbert F. Smit, MD, PhD, on Clinical Implications of Fam-trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

Posted: Monday, July 13, 2020

Egbert F. Smit, MD, PhD, of the Netherlands Cancer Institute, discusses the DESTINY-Lung01 study, its data on response rates with fam-trastuzumab deruxtecan, the frequent grade 3+ treatment-related adverse events, and how well tolerated this type of regimen might be in clinical practice.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.